- Biotechnology
- Friday, 05 Jun 2020
Healios Successfully Establishes Proprietary Universal Donor Cell Research Line
Healios plans to combine its UDC technology with its existing efforts in next-generation cancer-targeting immune cells, ophthalmology, organ buds and so on to create a line of regenerative medicine therapies with the highest possible safety and efficacy profile.
Typically, transplanted cells trigger an immune rejection response in patients whose HLA type does not match that of the cells. Therefore, doctors must administer an immunosuppressant drug during transplantation, which increases the burden on the patient's body. To avoid the administration of immunosuppressants, it is preferable to utilize autologous iPS cells produced by the patient's own cells, but the production process both takes a long time and is very expensive.
UDCs are iPS cells created using gene-editing technology that allows them to reduce the body's immune rejection response. The production of Healios' UDCs involves the removal of certain HLA genes that elicit a rejection response, the introduction of an immunosuppression gene to improve immune evasion, and the addition of a suicide gene serving as a safety mechanism, each in an allogeneic iPS cell. This next-generation technology platform allows for the creation of regenerative pharmaceutical products with enhanced safety and a lower risk of immune rejection, while preserving the inherent ability of iPS cells to replicate themselves continuously and their pluripotency in differentiating into various other kinds of cells.
Plans are underway at Healios to promote the internal development of regenerative pharmaceutical products that utilize UDCs and further reinforce the Company's pipeline. It is committed to working towards the early completion of a clinical-grade UDC line that meets global approvability standards.
Related Industry Updates
High-Resolution Melting Analysis Market Size 2021 Industry Analysis, Key Players, Growth Prospects, Revenue, Production, New Development, Business Share, Global Trends and Forecast To 2027
Mar 23, 2021
Jubilant Biosys Commences Major Capacity Expansions for its Drug Discovery Services Business
Nov 28, 2019
Hospital-Acquired Disease Testing Market: Business Opportunities, Current Trends and Forecast 2027
May 07, 2021
Organ Preservation Solution Market is expected to reach US$ 399,497.49 million by 2028.
May 12, 2023
Breast Implants Market 2021 Global Industry Analysis, Size, Investment Analysis, Trends, Growth, Development Factors, Future Scope, Challenges and 2027 Forecast Research Report
Feb 15, 2021
Efficacy Testing Market by Demand Analysis, Manufacturers Share, Regions, Risk Analysis, Driving Forces, Deployment Model, Production Scope, Type and Application, Forecast to 2027
Mar 24, 2021
Europe Fertilizer Additive Market is expected to reach US$ 590.5 Million by 2027 with CAGR of 2.5%
Oct 14, 2020